Skip to main content
Premium Trial:

Request an Annual Quote

Cynvenio ClearID Breast Cancer Test

Cynvenio Biosystems released its updated ClearID Breast Cancer blood test, which leverages a custom-developed NGS panel of 27 genes known to be altered in breast cancer. The updated test identifies circulating tumor cell burden and detects emerging genetic alterations that are associated with therapy resistance. The assay has been optimized to monitor patients with advanced breast cancer during the start of therapy and at regular intervals following treatment. 

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.